Demystifying particle-based oral vaccines

Gonzalez-Cruz, Pedro; Gill, Harvinder Singh

doi:10.1080/17425247.2021.1946511

Cited by 7 publications

(6 citation statements)

References 191 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oral vaccine can induce systemically as well as mucosal immunity and is more attractive than an injectable vaccine for the pain-free vaccination route. However, gastrointestinal barriers and antigen degradation are the major concerns when developing oral vaccines ( Gonzalez-Cruz and Gill, 2021 ). Yeast cell-wall, in addition to its natural adjuvant potential, can also play as a perfect immune protectant against gastrointestinal digestion.…”

Section: Discussionmentioning

confidence: 99%

In vivo Protein Interference: Oral Administration of Recombinant Yeast-Mediated Partial Leptin Reduction for Obesity Control

Yue

Wang

et al. 2022

Front. Microbiol.

View full text Add to dashboard Cite

Obesity-related diseases are always the major health problems that concern the whole world. Serial studies have reported that obesity development is closely related to the out-of-control leptin encoded by the obesity gene (ob). The latest report declaimed “Less Is More,” a model explaining that partial leptin reduction triggers leptin sensitization and contributes to obesity control. Here, we came up with a novel concept, in vivo protein interference (iPRTi), an interesting protein knock-down strategy for in vivo partial leptin reduction. First, the specific immune response against leptin induced by the oral administration of ob recombinant yeast was confirmed. Subsequentally, leptin resistance was observed in diet-induced obese mice, and oral administration with ob recombinant yeast declined the circulating leptin and reduced significantly the body weight gain. To further investigate whether the iPRTi strategy is capable of obesity management, the diet-induced obese mice were administrated with ob recombinant yeast. All the indexes examined including the circulating leptin, triglyceride, and total cholesterol, as well as food intake and weight gain, demonstrated a positive effect of the iPRTi strategy on obesity control. In short, this study provides a novel strategy for the potential application of recombinant yeast for the therapy of obese individuals with leptin resistance.

show abstract

Section: Discussionmentioning

confidence: 99%

In vivo Protein Interference: Oral Administration of Recombinant Yeast-Mediated Partial Leptin Reduction for Obesity Control

Yue

Wang

et al. 2022

Front. Microbiol.

View full text Add to dashboard Cite

show abstract

“…Oral vaccines could be formulated with freeze-dried algae or plant material expressing the antigen of interest. This could be especially convenient for booster vaccines used in developing countries, in which cold chain distribution and availability of sterile needles might compromise the coverage and rapid advances for the vaccination campaigns, although an expansion in the research to optimize such an approach is still needed [ 35 ].…”

Section: Discussionmentioning

confidence: 99%

An Algae-Made RBD from SARS-CoV-2 Is Immunogenic in Mice

et al. 2022

View full text Add to dashboard Cite

Despite the current advances in global vaccination against SARS-CoV-2, boosting is still required to sustain immunity in the population, and the induction of sterilizing immunity remains as a pending goal. Low-cost oral immunogens could be used as the basis for the design of affordable and easy-to-administer booster vaccines. Algae stand as promising platforms to produce immunogens at low cost, and it is possible to use them as oral delivery carriers since they are edible (not requiring complex purification and formulation processes). Herein, a Chlamydomonas-made SARS-CoV-2 RBD was evaluated as an oral immunogen in mice to explore the feasibility of developing an oral algae-based vaccine. The test immunogen was stable in freeze-dried algae biomass and able to induce, by the oral route, systemic and mucosal humoral responses against the spike protein at a similar magnitude to those induced by injected antigen plus alum adjuvant. IgG subclass analysis revealed a Th2-bias response which lasted over 4 months after the last immunization. The induced antibodies showed a similar reactivity against either Delta or Omicron variants. This study represents a step forward in the development of oral vaccines that could accelerate massive immunization.

show abstract

“…These include nanoparticle, microparticle-based vaccines, and virus-like particles (VLPs). Particle vaccines serve not only to deliver the antigen cargo to the host but also to modulate antigen release rates since prolonged antigen release may enhance the level and quality of immune responses [ 230 , 231 , 232 ]. Some KWC microbial vectors that express vaccine antigens can be considered biologically produced microparticles.…”

Section: Mucosal Vaccine Formulation and Delivery Strategiesmentioning

confidence: 99%

“…Other advantages of particle vaccines include (1) protection of the antigens; (2) due to the size of the particles, they can facilitate capture and uptake by APCs followed by maturation and stimulation of those APCs to further activate innate and adaptive immunities; (3) particle vaccines are versatile platforms to delivery several different antigens or combination of antigen with immune stimulatory molecules. Some particles can also act as adjuvants [ 232 , 233 ]. Indeed, some of the impressive effectiveness of the recently developed mRNA vaccines may be attributed to the adjuvating effects of the lipid nanoparticles used to encapsulate the mRNA component of the vaccines [ 234 ].…”

Section: Mucosal Vaccine Formulation and Delivery Strategiesmentioning

confidence: 99%

“…Several different chemical or biomaterials have been utilized to develop mucosal particle-based vaccines such as chitosan [ 235 , 236 ], poly lactic-co-glycolic acid (PLGA) [ 236 , 237 ], recombinant self-assemble protein subunits [ 238 , 239 , 240 ], lipid bilayers (FDA approved mRNA COVID-19 vaccines) [ 241 , 242 ], and VLPs that mimic viruses but without infectious components [ 243 , 244 , 245 ]. Those particle-based mucosal vaccines, either administrated alone or in combination with adjuvants, have been proven to be good at stimulating the immune system and eliciting effective immune protection against infections [ 230 , 232 , 244 , 246 ]. Particle-based vaccines beyond the licensed mRNA–lipid nanoparticle vaccines are still in the early stages of development, and more research is needed to determine their effectiveness and safety.…”

Section: Mucosal Vaccine Formulation and Delivery Strategiesmentioning

confidence: 99%

See 1 more Smart Citation

Vaccine Strategies to Elicit Mucosal Immunity

Song,

Mehl,

Zeichner

2024

Vaccines

View full text Add to dashboard Cite

Vaccines are essential tools to prevent infection and control transmission of infectious diseases that threaten public health. Most infectious agents enter their hosts across mucosal surfaces, which make up key first lines of host defense against pathogens. Mucosal immune responses play critical roles in host immune defense to provide durable and better recall responses. Substantial attention has been focused on developing effective mucosal vaccines to elicit robust localized and systemic immune responses by administration via mucosal routes. Mucosal vaccines that elicit effective immune responses yield protection superior to parenterally delivered vaccines. Beyond their valuable immunogenicity, mucosal vaccines can be less expensive and easier to administer without a need for injection materials and more highly trained personnel. However, developing effective mucosal vaccines faces many challenges, and much effort has been directed at their development. In this article, we review the history of mucosal vaccine development and present an overview of mucosal compartment biology and the roles that mucosal immunity plays in defending against infection, knowledge that has helped inform mucosal vaccine development. We explore new progress in mucosal vaccine design and optimization and novel approaches created to improve the efficacy and safety of mucosal vaccines.

show abstract

Demystifying particle-based oral vaccines

Cited by 7 publications

References 191 publications

In vivo Protein Interference: Oral Administration of Recombinant Yeast-Mediated Partial Leptin Reduction for Obesity Control

In vivo Protein Interference: Oral Administration of Recombinant Yeast-Mediated Partial Leptin Reduction for Obesity Control

An Algae-Made RBD from SARS-CoV-2 Is Immunogenic in Mice

Vaccine Strategies to Elicit Mucosal Immunity

Contact Info

Product

Resources

About